Results 71 to 80 of about 30,610 (250)

Natural Killer Cells in Paediatric Soft Tissue Sarcomas: A Systematic Review

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Paediatric soft tissue sarcomas (pSTS) are a rare and heterogeneous group of malignant tumours arising in tissues of mesenchymal origin. The role of natural killer (NK) cells in pSTS remains poorly understood, with evidence fragmented across small preclinical studies and early‐phase clinical trials.
Raya Dean, Lara V. Graham, Christina Putnam, Rosa Gomes Alves Martins, Daniel T. Harding, Tim J. Underwood, Zoë S. Walters, Matthew D. Blunt   +7 more
wiley   +1 more source

Development and Implementation of a Disease‐Targeted Storybook as a Clinical Tool for Children With Acute Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Although significant progress has been made in childhood leukemia survival, healthcare providers, and caregivers often face challenges in explaining this disease to patients. Disease‐targeted storybooks have been proposed as a tool to facilitate the understanding of diagnoses and treatment.
Nutvipha Ummartyotin, Usanarat Anurathapan, Rawiwan Roongpraiwan, Potchanee Dandamrongrak, Siriporn Nakhonchai, Pawin Numthavaj, Vilawan Chirdkiatgumchai   +6 more
wiley   +1 more source

Preventive and Remedial Actions in Corporate Reporting Among "Addiction Industries": Legitimacy, Effectiveness and Hypocrisy Perception. [PDF]

J Bus Ethics, 2023
Acuti D, Bellucci M, Manetti G.
europepmc   +1 more source

Corporate Integrated Reporting

, 2022
The goal of every company should not be profit exclusively but also public welfare and social responsibility. Traditional financial reporting of companies was not sufficient to monitor the sustainable development of companies and their impact on the wider community.
openaire   +1 more source

Animal‐Assisted Activities With Therapy Dogs in Pediatric Oncology: A Multicenter Survey of the Current Status, Implementation, and Challenges in Germany, Austria, and Switzerland

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Animal‐assisted activities (AAAs) with therapy dogs have shown positive effects on patient well‐being and quality of life in various areas of medicine, including pediatric oncology. However, research on this topic is limited. The aim of this study is to present the current status of AAA in pediatric oncology in Germany, Austria, and
Jan‐Marius Wedig, Birgit Burkhardt, Christof M. Kramm, Kira Ostermann, Sarah C. Goretzki, Uta Dirksen, Nico Kurpiers, Michael M. Schündeln   +7 more
wiley   +1 more source

Corporate Report

European Cardiology Review, 2006
  +6 more sources

Understanding and improving the language of business: How accounting and corporate reporting research can better serve business and society. [PDF]

J Bus Econ, 2023
Fülbier RU, Sellhorn T.
europepmc   +1 more source

Determining Parental Factors for Clinical Trial Attrition in Pediatric Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background/Objectives Despite high enrollment rates on Children's Oncology Group (COG) protocols, attrition after initial consent is challenging, introducing bias and prolonging trial completion. While adult oncology literature has identified predictors of withdrawal, little is known about caregiver decision‐making for child participation in ...
Kimberly L. Stathas, Jakob Q. Weiss, Kellee N. Parker, Cathy Lee‐Miller   +3 more
wiley   +1 more source

Cultural Influence on Perceived Usefulness of Islamic Corporate Reporting Model

Jurnal Akuntansi dan Auditing Indonesia, 2009
The objective of this study is to examine the cultural influence on the per-ceived usefulness of Islamic corporate reporting model. This study attempts to un-derstand the antecedents of perceived usefulness of Islamic corporate reporting model.
Dwi Ratmono, Fuad Mas’ud
doaj  

Administering Blinatumomab via Continuous Intravenous Infusion in Pediatric Patients—A Single‐Institution Retrospective Review

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Blinatumomab, a CD19xCD3 bispecific T‐cell engager, has become standard therapy for children with de novo B‐cell acute lymphoblastic leukemia (B‐ALL). This retrospective review describes the experience of blinatumomab administration in pediatric patients.
Julia M. Hurley, Ryleigh Krueger, Kellie Joyce, James Stanley, Mary Waskerwitz‐Freyer, Marielle Klunder, David J. Hoogstra   +6 more
wiley   +1 more source